Teladoc Health Inc. (TDOC)

TDOC posts narrower Q2 loss and trims costs, but shares dip as U.S. revenues and visit volumes decline.

Teladoc Health remains a deep value play at $7, trading at just 5-6x EBITDA, but lacks a clear growth catalyst. Revenue and user metrics are declining across core segments, with BetterHelp and Chronic...

Teladoc's Q2 2025 earnings reaffirm strong free cash flow guidance, with the potential to reach $220 million in the next twelve months. Despite an attractive 7x next year's free cash flow valuation, r...

Teladoc Health, Inc. Q2 2025 Earnings Conference Call July 29, 2025 4:30 PM ET Company Participants Charles Divita - CEO & Director Mala Murthy - Chief Financial Officer Michael Minchak - Vice Preside...

The headline numbers for Teladoc (TDOC) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates...

Teladoc (TDOC) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.28 per share a year ago.

Hims & Hers and Teladoc Health are reshaping virtual care, but which has the edge in earnings growth and strategic expansion? Let's see.

Teladoc (TDOC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

I've upgraded Teladoc to a tepid buy—not a full conviction call, but the numbers finally tilt in its favor. I believe the company's innovative platform positions it as a leader in digital healthcare, ...

Teladoc (TDOC) concluded the recent trading session at $8.58, signifying a -1.49% move from its prior day's close.